is-1

1

1

1

1

1

1

1

1

1

1

1

Performed Clinical Trials
with NAC-GED-0507 - Acne

STUDY Tested Product

Nr subjects exposed
Study Design/Population Treatment
Duration
GED-0507-ACN-01-14
ACNE
Phase 1
NAC-GED-0507 Gel 1%
NAC-GED-0507 Gel 2%

Active: 48
Open label clinical study to evaluate the dermal safety profile of 12-weeks topical administration of NAC-GED-0507 Gel, 1% and 2%, in patients with mild to moderate facial acne vulgaris
Age: 14-30 years (males) and 18-30 years (females)
12 weeks
Once daily
NAC-GED-0507-ACN-02-17
ACNE
Phase 1
NAC-GED-0507 Gel 5%

Active: 25
An open label clinical study to evaluate the long-term dermal safety profile of 12-weeks topical administration of NAC-GED-0507 Gel 5% in patients with facial acne
Age: 12-30 years (males) and 18-30 years (females)
12 weeks
Once daily
GED-0507-ACN-01-16
ACNE
Phase 2a
NAC-GED-0507 Gel 1%
NAC-GED-0507 Gel 2%
Placebo Gel (vehicle)

Active: 100
Placebo: 47
Double-blind, randomised, placebo-controlled clinical study to evaluate the efficacy and safety of NAC-GED-0507-Gel, 1% and 2%, applied once daily for 12 weeks in patients with mild to moderate facial acne vulgaris
Age: 14-30 years (males) and 18-30 years (females)
12 weeks
Once daily
NAC-GED-0507-ACN-01-18
ACNE
Phase 2b
NAC-GED-0507 Gel 2%
NAC-GED-0507 Gel 5%
Placebo Gel (vehicle)

Active: 300
Placebo: 150
A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of NAC-GED-0507 gel, 2% and 5%, applied once daily for 12 weeks in patients with facial acne vulgaris
Age 12-30 years
12 weeks
Once daily

Pipeline

Discover more

PPARy PLATFORM

Discover more

Lead Product

Discover more

NAC-GED-0507

Discover more

Network

Discover more

Conclusions

Discover more